Related references
Note: Only part of the references are listed.Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes
Jia Ruan et al.
BLOOD (2013)
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T. Stopeck et al.
BLOOD (2012)
Central nervous system pericytes in health and disease
Ethan A. Winkler et al.
NATURE NEUROSCIENCE (2011)
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T. Stopeck et al.
LEUKEMIA & LYMPHOMA (2009)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Transforming growth factor β1 induction of vascular endothelial growth factor receptor 1:: Mechanism of pericyte-induced vascular survival in vivo
SC Shih et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
